REG - Nuformix PLC - NXP004 Patent

NuformixAnnouncement

28/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220328:nRSb1492Ga&default-theme=true

RNS Number : 1492G  Nuformix PLC  28 March 2022

28 March 2022

 

Nuformix plc

 

("Nuformix" or the "Company")

 

NXP004 Patent

 

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce the publication of an international patent in relation to the
Company's NXP004 asset, which comprises novel forms of olaparib (the
"Patent").  Olaparib is currently marketed by AstraZeneca, under the
Lynparza® brand name for the treatment of adults with suspected deleterious
germline or somatic BRCA gene mutated ovarian, breast, or pancreatic cancer,
or for suspected deleterious germline or somatic HRR gene mutated prostate
cancer.

 

The application for the Patent, relating to new olaparib oxalic acid
cocrystals, their therapeutic uses and pharmaceutical compositions containing
them, was made by the Company's wholly owned subsidiary Nuformix Technologies
Limited and was filed in September 2020.  The Company filed a second patent
application, complementing the Patent, in November 2021 and this remains
pending.

 

The olaparib oxalic acid cocrystals covered by the Patent may be used in the
same way as olaparib. Olaparib is useful in treating diseases that benefit
from PARP (Poly ADP Ribose Polymerase) inhibition. These include cancer,
fibrosis, inflammatory conditions (e.g. asthma, colitis, arthritis),
neurological diseases (e.g. neurodegeneration, neurotrauma, stroke),
cardiovascular conditions, ophthalmic degenerative diseases, vascular diseases
(e.g. diabetic complications, atherosclerosis), and various forms of critical
illness (e.g. septic shock, ALI, acute liver failure). The olaparib oxalic
acid cocrystals covered by the Patent may, therefore, ultimately be useful for
the treatment of such diseases, disorders, and conditions.

 

The Company looks forward to providing further updates on progress with NXP004
and the Company's other assets in due course.

 

Commenting, Alastair Riddell, Executive Chairman of Nuformix, said: "We are
pleased to see the progression of the application for the Company's first
patent in relation to NXP004 to the publication stage.  We believe NXP004 has
significant potential and look forward to the granting of the Patent in due
course.  We are continuing to conduct further research and development
activities on NXP004, as well as investigating future commercial
opportunities.  Whilst there remains much to be done, I look forward to
making further announcements on our progress in the future."

 

Enquiries:

 

 Nuformix plc
 Dr Alastair Riddell, Executive Chairman           Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCLDLFLLXLLBBK